Barclays Maintains Equal-Weight on Chemours, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Michael Leithead maintains an Equal-Weight rating on Chemours (NYSE:CC) but lowers the price target from $22 to $21.
September 25, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Michael Leithead maintains an Equal-Weight rating on Chemours but lowers the price target from $22 to $21, indicating a slightly less optimistic outlook.
The lowering of the price target by Barclays suggests a slightly less optimistic view on Chemours' future performance, which could lead to a short-term negative impact on the stock price. The Equal-Weight rating indicates a neutral stance, but the reduced price target may influence investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100